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Abstract
Background: Glucosamine, a common dietary supplement, has a possible anti-sarcoma effect. However, an
understanding of the underlying mechanism of such an effect is limited. For this study we hypothesized that
glucosamine suppresses the basal level of matrix metalloproteinase expression in human osteosarcoma cell lines.
Methods: We examined the osteosarcoma cell lines, MG-63 and SaOS-2. Cells were exposed to 0, 10, 50 and
100 μg/ml glucosamine sulfate for 48 h and treatment toxicity was determined through measurement of cell
viability and proliferation. Relative gene expression of matrix metalloproteinase (MMP)-2, -3 and -9 was quantified
by real-time polymerase chain reaction. Protein levels of MMP-2 and -9 were assessed by ELISA.
Results: Administration of 10, 50 or 100 μg/ml glucosamine sulfate had no effect on the cell viability of MG-63 and
SaOS-2 cells. A significant reduction of MMP expression in both cell lines was observed only for MMP-3, while a
decrease in MMP-9 was seen in SaOS-2 cells. The expression of MMP-2 was not significantly affected in either cell
line. Protein level of MMP-3 was reduced in both cell lines upon stimulation with 10 μg/ml glucosamine sulfate
whereas for MMP-9 a decrease could only be observed in SaOS-2 cells.
Conclusion: In this study, we found a pronounced suppressive effect of glucosamine sulfate particularly on MMP-3
and also MMP-9 mRNA and protein levels in osteosarcoma cell lines in vitro. The data warrants further
investigations into the potential anti-tumor efficacy of glucosamine sulfate in osteosarcoma.
Keywords: Glucosamine sulfate, Neutraceutical, Dietary supplement, Osteosarcoma, Matrix metalloproteinase,
MMP-3, MMP-9
Abbreviations: CTGF, Connective tissue growth factor; DMEM, Dulbecco’s Modified Eagle Medium; ELISA, Enzyme-linked
immunosorbent assay; FBS, Fetal bovine serum; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; Il1ß, Interleukin-1ß;
JNK, c-jun-amino-terminal kinase; MAPK, Mitogen-activated protein kinase; MMP, Matrix metalloproteinase;
PCR, Polymerase chain reaction; PMA, Phorbol 12-myristate 13-acetate
Background
In a landmark preclinical study Quastel and Cantero ex-
amined the effect of glucosamine on tumor growth in
vivo [1]. They observed that daily administration of glu-
cosamine reduced tumor growth and prolonged overall
survival in mice bearing sarcoma 37 tumors [1].
Importantly, no toxicity was associated with the glucosa-
mine treatment. More recently, extended clinical trials
in more common tumor types underscored the potential
anti-tumor effect of glucosamine in patients [2]. For ex-
ample, the prospective VITamins And Lifestyle (VITAL)
study showed that dietary glucosamine supplementation
of glucosamine reduces the incidence of colorectal and
lung cancer by more than 25 %, resulting in a 13 % re-
duction in cancer mortality [3, 4].
Despite the evidence for a possible anti-sarcoma effect
of nutritional glucosamine supplementation, our under-
standing of the underlying mechanisms is limited. Early
studies by Molnar et al. were restricted to describing the
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morphological changes that occur in Sarcoma 180 cells, a
transplantable mouse sarcoma isolated from ascites [5, 6].
More recent work by Gervasi and co-workers, has investi-
gated the effect of glucosamine supplementation in
human HT1080 fibrosarcoma cells. They found that treat-
ment with N-acetyl-D-glucosamine reduces concanavalin
A-induced matrix metalloproteinase (MMP)-2 activity [7].
These findings have been corroborated by two studies
conducted in Kim’s laboratory; these studies show that
an amino derivative of glucosamine reduces phorbol 12-
myristate 13-acetate (PMA)-induced upregulation of
MMP-2 and MMP-9 in HT-1080 cells was reduced in the
presence of an amino derivative of glucosamine [8, 9].
They also demonstrated that glucosamine derivatives sup-
press MMP-2 and -9 gene expression in addition to de-
creasing the proteolytic processing of MMP precursors [8,
9]. Further, work by Lin et al. has shown that glucosamine
represses interleukin-1ß (Il1ß)-induced expression of
MMP-3 in the SW-1353 chondrosarcoma cell line [10].
Interestingly, despite of numerous regulatory processes
from MMP gene expression to the active enzyme, previ-
ous studies with colorectal and breast cancer specimens
showed a close correlation between the level of gene ex-
pression and disease-free survival [11, 12].
Based on these studies, we hypothesized that (1) the
reported effects of glucosamine are most probably not
limited to the reported sarcoma cell types and may ex-
tend to osteosarcoma cells, (2) glucosamine suppresses
the basal expression of MMPs in the absence of specific
MMP inducers such as concanavalin A or PMA, and (3)
glucosamine potentially suppresses MMP-3, MMP-9 and
MMP-2 expression to different extents. Herein, we re-
port, for the first time, that glucosamine sulfate exerts a
pronounced suppressive effect on MMPs, particularly on
MMP-3 and -9 in osteosarcoma cell lines in vitro.
Methods
Materials
All reagents were purchased from Sigma Aldrich
(Sigma-Aldrich, St. Louis, USA) unless stated other-
wise. Nutritional grade glucosamine sulfate powder
(2(C6H13NO5)
.H2SO4) was purchased from Vita Natura
(Bonn, Germany). A glucosamine sulfate solution was pre-
pared to a final concentration of 100 μg/ml in cell culture
medium (detailed below). The solution was sterile filtered,
aliquoted, and stored at −20 °C until further use.
Cell culture
MG-63 osteosarcoma cells were obtained from the
American Type Culture Collection (ATCC, Manassas,
USA). SaOS-2 cells were purchased from Deutsche
Sammlung für Mikroorganismen (DMSZ, Braunschweig,
Germany). Both cell lines were cultured as a mono-
layer in Dulbecco’s Modified Eagle Medium (DMEM)
supplemented with 1 % MEM-Vitamine, 1 % glutamine,
10 % fetal bovine serum (FBS), 1 U/mL penicillin/strepto-
mycin and 2 % HEPES buffer (all obtained from Biochrom,
Berlin, Germany) at 37 °C and 5 % CO2. Cells were pas-
saged at 80–90 % confluency and culture medium was re-
placed every second day.
Glucosamine sulfate treatment
Treatments were performed in a 6 well plates. MG-63
(2 × 106) and SaOS-2 (4 × 106) were seeded in 3 ml of
medium and cultured for 24 h. Different seeding dens-
ities were used to compensate for the higher prolifera-
tion rate of MG-63 cells. The following day, the medium
was replaced with fresh medium containing 2 % FBS and
a final concentration of 10, 50 or 100 μg/ml glucosamine
sulfate (achieved with a 1:9, 1:1 and 1:0 dilution of the
glucosamine stock solution) and cells were incubated for
48 h. Following the incubation period, cells were dissoci-
ated with trypsin, counted and collected by centrifuga-
tion. RNA was then isolated from the cell pellets as
described below.
Toxicity assay
To detect potential toxicity associated with glucosamine
sulfate treatment and exclude a downregulation of
mRNA and protein expression due to cytotoxic cell
death, a WST-1 cytotoxicity assay (Roche, Mannheim,
Germany) was performed. Briefly, 2 × 105 MG-63 and
4 × 105 SaOS-2 were seeded in 200 μL medium in 48
well plates. Cells were then stimulated with different
concentrations of glucosamine sulfate for 48 h (de-
scribed above) prior to addition of 20 μl of WST reagent
were added. Plates were incubated for 2 h before absorp-
tion was measured at 450 nm and a reference wave-
length of 690 nm.
Quantitative gene expression analysis
RNA was isolated from cells using the RNeasy Tissue Kit®
(Qiagen, Hilden, Germany) according to the manufac-
turer’s instructions. In brief, MG-63 or SaOS-2 cells were
resuspended in RLT buffer, transferred to a Qiashredder®
and then lysed. RNA from lysates was immobilized on a
silica matrix and eluted with distilled water. Harvested
RNA was quantified by photometry.
Isolated RNA was transcribed to cDNA using
QuantiTect® Reverse Transcriptions Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions.
The relative gene expression of MMP-2, -3 and -9 was quan-
tified by real-time polymerase chain reaction (PCR) using a
thermo cycler with TaqMan® Array and specific primers
(MMP-2: Hs01548727_m1; MMP-3: Hs01548727_m1;
MMP-9: Hs01548727_m1; glyceraldehyde 3-phosphate
dehydrogenase (GAPDH): NM_002046.3) (Applied Biosys-
tems, Grand Island, USA). GAPDH was used as internal
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control. The thermal cycler conditions were: 40 cycles
consisting of a 15 s denaturation phase at 95 °C and
a combined 1 min annealing and extension phase at
60 °C.
Enzyme-linked immunosorbent assay (ELISA)
Protein analysis was performed from cells stimulated
with 10 μg/ml glucosamine sulfate. After washing with
PBS, a precipitation step with acetone and resuspension
with cell extraction buffer (Invitrogen™, Frederick, USA)
was performed.
Sandwich ELISA Kits for human MMP-3 and MMP-9
(Invitrogen™, Frederick, USA) were used for quantitative
analysis according to the manufacturer’s instructions. In
brief, 50 μl of diluted cell lysate was transferred to each
microplate well previously coated with monoclonal anti-
body. After incubation with MMP-3 and MMP-9 specific
detection antibodies as well as substrate solution the en-
zyme concentration was quantified spectrophotometric-
ally in an ELISA Reader at 450 nm.
Statistics
Quantitative PCR and ELISA data were compared using
SPSS software (IBM, Armonk, USA) and the t-test for
unpaired samples. The results are shown as mean ±
standard deviation. A p-value of ≤0,05 was considered
statistically significant.
Results
To assess the effect of glucosamine sulfate on MMP ex-
pression, glucosamine sulfate concentrations of 10 μg/ml,
50 μg/ml and 100 μg/ml were used. These concentrations
were based on previous reports [8, 13]. Prior to quantita-
tive analysis of MMP gene and protein expression, the po-
tential cytotoxicity of the glucosamine sulfate treatment
was examined. Glucosamine sulfate treatment did not sig-
nificantly reduce the viability of either MG-63 (Fig. 1a) or
Saos-2 (Fig. 1b) cells, indicating that the examined con-
centrations were not toxic.
Subsequent analysis of MMP gene expression in re-
sponse to 10 μg/ml glucosamine sulfate administration
demonstrated a significant reduction of MMP-3 by ap-
proximately 68 % in MG-63 cells (p = 0,037) and 63 % in
SaOS-2 cells (p = 0,003) compared to the untreated
control (Fig. 2). Although MMP-9 expression was not
significantly reduced in MG-63 cells, it was significantly
reduced by approximately 34 % in SaOS-2 cells (p = 0,04;
Fig. 2). Our analysis indicated that 10 μg/ml of glucosa-
mine sulfate has no significant effect on MMP-2 gene
expression in either MG-63 or Saos-2 cells (Fig. 2).
Increasing the glucosamine sulfate concentration to
50 μg/ml significantly reduced MMP-3 gene expression by
approximately 74 % in MG-63 cells (p = 0,021), while the
reduction of MMP-3 in Saos-2 cells did not reach
significance (Fig. 3). The expression of MMP-9 and
MMP-2 was not significantly altered by 50 μg/ml
glucosamine sulfate in either cell line (Fig. 3). Simi-
lar to the effect of 50 μg/ml glucosamine sulfate on
MMP-3 expression in MG-63 cells, administration of
100 μg/ml resulted in a significant decrease of MMP-3 ex-
pression by about 73 % in MG-63 cells (p = 0,021; Fig. 4).
However, the gene expressions of MMP-9 and MMP-2
were not significantly altered by 100 μg/ml glucosamine
sulfate.
Protein expression analysis demonstrated similar re-
sults. Upon administration of 10 μg/ml glucosamine sul-
fate MMP-3 protein level was reduced by about 23 % in
MG-63 (p = 0,60) and 28 % in SaOS-2 cells (p = 0,38)
(Fig. 5a). MMP-9 revealed an insignificant increase of
approximately 22 % upon stimulation with 10 μg/ml GlS
in MG-63 cells (p = 0,54). SaOS-2 cells exhibited a de-
crease of MMP-9 protein level of about 29 % (p = 0,49)
(Fig. 5b).
Fig. 1 Cell viability as absorbance at A450–A690 in a WST-1 assay in
the unstimulated control and upon administration of 10, 50 and
100 μg/ml glucosamine sulfate in MG-63 (a) and SaOS-2 cells (b); a
statistical comparism was carried out for the control and each of the
glucosamine sulfate treated groups; * indicates statistical significance
with p≤ 0,05
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Discussion
In this study, we observed that (1) glucosamine sulfate
inhibits MMP gene and protein expressions in MG-63
and SaOS-2 osteosarcoma cell lines, (2) glucosamine sul-
fate suppresses basal MMP expression in osteosarcoma
cells, and (3) glucosamine sulfate most significantly
affects MMP-3 expression compared to MMP-9 and
MMP-2.
MMPs are overexpressed in many different types of
cancer, and consequently these proteinases are fre-
quently investigated therapeutic target [14]. To date, a
considerable number of pharmacological MMP inhibi-
tors have been developed and tested in clinical trials
[15]. However, their therapeutic efficacy thus far has
proved limited [16]. The potential reasons for this lack
of efficacy include: (1) limitations associated with the ex-
tensive homology between MMP catalytic domains; none
of the tested drugs have been highly selective for specific
MMPs, which could result in anti-tumor MMPs being
inhibited; (2) unanticipated long-term drug intolerance
that can reduce drug compliance; (3) the exclusion of
early-stage cancer patients from clinical trials; these
patients are anticipated to benefit most from MMP
blockade; and (4) the drug doses used have been based
on short-term kinetic studies in healthy volunteers and
are not necessarily predictive of chronic therapeutic drug
levels in cancer [16]. Thus, alternative strategies for
MMP inhibition in cancer patients are of considerable
interest.
In the present study, we demonstrate that a relatively
low concentration of 10 μg/ml glucosamine sulfate re-
duces MMP-3 expression more than 50 % in both of the
osteosarcoma cell lines investigated. This finding is par-
ticularly relevant because recent work by Tsai et al.
found that MMP-3 is overexpressed in human osteosar-
comas [17]. Further, their data identified miR-519d
down-regulation via connective tissue growth factor
(CTGF) signaling as a pathway osteosarcoma cells utilize
to upregulate MMP-3 and MMP-2 expression [17]. But
also mitogen-activated protein kinase (MAPK) pathways
seem to play a pivotal role in mediating inflammatory and
oncogenic signals and consequently inducing MMP-3
expression [18]. In this context Scotto d’Abuso and
coworkers identified a decreased phosphorylation of
Fig. 2 Relative gene expression of MMP-3, -9 and -2 in MG-63 and SaOS-2 cells upon administration of 10 μg/ml glucosamine sulfate; a statistical
comparism was carried out for the control and each of the glucosamine sulfate treated groups; * indicates statistical significance with p≤ 0,05
Fig. 3 Relative gene expression of MMP-3, -9 and -2 in MG-63 and SaOS-2 cells upon administration of 50 μg/ml glucosamine sulfate; a statistical
comparism was carried out for the control and each of the glucosamine sulfate treated groups; * indicates statistical significance with p≤ 0,05
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c-jun-amino-terminal kinase (JNK) and p38 in human
chondrocytes upon stimulation with glucosamine [19].
Moreover, their study showed a decreased activity of
c-jun and junD depicting important transcription fac-
tors of MMPs [19]. The decreased phosphorylation of
MAPKs by glucosamine may, in turn, be explained by
coupling of N-acetylated glucosamine (N-acetylgluco-
samine) to serine or threonine residues of those
proteins [19]. This O-glycosylation is thought to act
in a manner analogous to phosphorylation [20, 21]. In
support of these findings, recent clinical studies have
demonstrated a close correlation between MMP-3
expression and the development of lung metastases in
breast and lung cancers [22, 23]. In our study, which
analized the expression of three MMPs, we found that
glucosamine sulfate treatment exerted an unexpect-
edly specific effect. For example, the expression of
MMP-3 was significantly reduced by glucosamine sul-
fate, but MMP-2 expression was not. In fact, a mod-
est, yet statistically insignificant, increase was seen.
Although these observations require further investiga-
tions, they suggest, that glucosamine sulfate is not a
broad MMP inhibitor, but may rather be useful for
more specific MMP suppression.
The data presented here support the potential use of
glucosamine sulfate as a nutritional supplement in
osteosarcoma patients for two main reasons. First, the
glucosamine used in this study was a commercially avail-
able dietary glucosamine, formulated as glucosamine sul-
fate, which, together with glucosamine hydrochloride
constitutes the principle nutritional formulation for glu-
cosamine supplements [24, 25]. Previous studies have
used either the non-dietary quaternized amino glucosa-
mine [9] and N-acetyl-D-glucosamine [7], or sulfated
glucosamine synthesized in-house [8]. Second, the most
pronounced effect of glucosamine sulfate was observed
at a concentration of 10 μg/ml. This concentration is
within the range of the human serum concentrations
that can be achieved with oral glucosamine intake, as
previously published by Biggee et al. [26]. As such, it can
be foreseen that glucosamine sulfate supplementation
during osteosarcoma treatment could have a potentially
beneficial effect. Upon diagnosis the vast majority of pa-
tients are treated with multi-agent neoadjuvant chemo-
therapy, followed by wide surgical resection of the
tumor and adjuvant chemotherapy. Such regimes result
in excellent primary tumor control, however, pulmonary
metastases, which are challenging to control, develop in
more than 30 % of patients [27]. One of the advantages
of glucosamine of glucosamine dietary supplementation
in osteosarcoma patients is that it will, most likely,
Fig. 4 Relative gene expression of MMP-3, -9 and -2 in MG-63 and SaOS-2 cells upon administration of 100 μg/ml glucosamine sulfate; a statistical
comparism was carried out for the control and each of the glucosamine sulfate treated groups; * indicates statistical significance with p≤ 0,05
Fig. 5 Protein levels as absorbance at A450–A690 in an ELISA
assay of (a) MMP-3 and (b) MMP-9 in MG-63 and SaOS-2 cells upon
administration of 10 μg/ml glucosamine sulfate; * indicates statistical
significance with p≤ 0,05
Pohlig et al. BMC Complementary and Alternative Medicine  (2016) 16:313 Page 5 of 7
integrate seamlessly into the standard treatment proto-
col. Other advantages of glucosamine dietary supple-
mentation, namely the lack of toxicity, unrestricted
availability, and low treatment costs this would enable
supplementation to start permit upon initial diagnosis
and continue over long periods of time, past primary
tumor treatment. This may eventually reduce the inci-
dence of pulmonary metastasis from osteosarcoma. As
such, we anticipate that glucosamine sulfate treatment
during osteosarcoma therapy will receive further attention,
similar to the renewed interest in other nutraceuticals in
augmenting standard cancer therapy [28]. However, we
appreciate that the nutritional translation of the present
findings will require a substantial further investigations in
vitro and in preclinical models.
Conclusion
In conclusion, we have shown that glucosamine sulfate
exerts a pronounced suppressive effect on MMPs in
osteosarcoma cell lines in vitro; this effect was most pro-
nounced for MMP-3 and MMP-9 to a lesser extent. The
data warrants further studies into the potential antitu-
mor effect of glucosamine sulfate in osteosarcoma.
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